AlphaRx continues to build up Indaflex for the Chinese market AlphaRx, Inc. , has been suggested by Cypress Biosciences , its development partner for Indaflex, that Cypress is not funding advancement of Indaflex. Notwithstanding to the termination of all Indaflex activity in the U facts .S.A., AlphaRx continues to develop Indaflex for the Chinese market. AlphaRx is operating diligently using its regulatory consultants in the planning for submission of a CTA with the China SFDA to be able to begin individual trials in China.
Alnylam receives U.S. Patent allowance for LNP platform Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics organization, announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for patent software number 12/813,448, within the company’s proprietary second era lipid nanoparticle platform, like the ‘MC3’ lipid. ‘We are very happy with the USPTO’s allowance of claims for this important patent related to our second generation LNPs, hence acknowledging the novelty of the MC3 lipid for systemic delivery of RNAi therapeutics,’ stated Laurence Reid, Ph.D., Senior Vice Chief and President Business Officer of Alnylam.